He added, "In the past week we have completed three business development transactions under financial terms that are primarily success-based that add an attractive commercial product and two development products to our portfolio. We now have a diverse development pipeline with three late-stage product candidates - RHUCIN, budesonide MMX?® and rifamycin SV MMX?® - in Phase III clinical programs and a promising earlier stage anti-VLA-1 antibody, all of which offer significant commercial potential. Last week we announced the expansion of our commercial portfolio with the addition of CYCLOSET?®, an FDA-approved, novel product to treat type 2 diabetes. CYCLOSET is an excellent strategic fit with GLUMETZA?® that allows us to leverage our sales organization. We believe that our cash, cash equivalents and short-term investments and borrowings available under our line of credit with Comerica Bank will be sufficient to fund our operations at least through the end of 2011."

Source : Santarus, Inc.